BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/23/2021 6:30:08 AM | Browse: 690 | Download: 1952
 |
Received |
|
2021-05-09 13:35 |
|
Peer-Review Started |
|
2021-05-09 13:38 |
|
First Decision by Editorial Office Director |
|
2021-06-06 03:29 |
|
Return for Revision |
|
2021-06-06 03:29 |
|
Revised |
|
2021-08-19 18:26 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-09-13 02:28 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-09-17 02:56 |
|
Articles in Press |
|
2021-09-17 02:56 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-11-19 02:34 |
|
Publish the Manuscript Online |
|
2021-11-23 06:30 |
| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Prospective Study |
| Article Title |
Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Piyatida Chuengsaman, Surapong Narenpitak and Suchai Sritippayawan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Piyatida Chuengsaman, MD, Doctor, Doctor, Banphaeo Dialysis Group, Banphaeo Hospital (Public Organization), 198 Moo 1 Banphaeo, Banphaeo 74120, Samutsakhon, Thailand. pchuengsaman@gmail.com |
| Key Words |
Recombinant human erythropoietin; Anemia; Peritoneal dialysis; Chronic kidney disease; Epoetin alfa |
| Core Tip |
This was an open-label, single-arm, prospective, multicenter study of Hema-Plus®, a recombinant human erythropoietin (rHuEPO) for management of anemia in 30 Thai chronic kidney disease patients who started peritoneal dialysis with hemoglobin (Hb) lower than 9.5 g/dL and who had not previously received epoetin. The results showed that the rHuEPO could significantly increase Hb from baseline throughout the 12-wk treatment duration with acceptable safety profile. The quality of life (QoL) scores at week 12 assessed using KDQOL-36 were significantly increased from baseline in all domains. |
| Publish Date |
2021-11-23 06:30 |
| Citation |
Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121 |
| URL |
https://www.wjgnet.com/2220-6124/full/v10/i6/109.htm |
| DOI |
https://dx.doi.org/10.5527/wjn.v10.i6.109 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
